Efficacy and safety of lebrikizumab is maintained to two years in patients with moderate-to-severe atopic dermatitis

被引：0
|
作者：
Guttman-Yassky, Emma [1 ]
Weidinger, Stephan [2 ]
Simpson, Eric [3 ]
Gooderham, Melinda [4 ,5 ]
Irvine, Alan [6 ]
Spelman, Lynda [7 ,8 ]
Silverberg, Jonathan [9 ]
Elmaraghy, Hany [10 ]
DeLuca-Carter, Louise [10 ]
Piruzeli, Maria Lucia Buziqui [10 ]
Hu, Chaoran [10 ]
Yang, Fan Emily [10 ]
Pierce, Evangeline [10 ]
Bardolet, Laia [11 ]
Thaci, Diamant [12 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] Univ Hosp Schleswig Holstein, Kiel, Germany
[3] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[4] Prob Med Res, SKiN Dermatol, Peterborough, ON, Canada
[5] Queens Univ, Peterborough, ON, Canada
[6] Childrens Hlth Ireland, Dublin, Ireland
[7] Verac Clin Res, Woolloongabba, Qld, Australia
[8] Prob Med Res, Woolloongabba, Qld, Australia
[9] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA
[10] Eli Lilly & Co, Indianapolis, IN 46285 USA
[11] Almirall SA, Barcelona, Spain
[12] Univ Lubeck, Inst & Comprehens Ctr Inflammatory Med, Lubeck, Germany
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 190卷
关键词：
atopic dermatitis; efficacy; lebrikizumab; phase; 3; trials; safety;
D O I：
10.1093/bjd/ljad498.005
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
494
引用
收藏
页码：II3 / II4
页数：2
相关论文
共 50 条
  • [11] MAINTENANCE OF LEBRIKIZUMAB EFFICACY IN PATIENTS WITH MODERATE -TO -SEVERE ATOPIC DERMATITIS AND ATOPIC COMORBIDITIES
    Sher, E.
    Golant, A.
    DeBruin-Weller, M.
    Dawson, Z.
    Atwater, A.
    Zhong, J.
    Carrascosa, J.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2024, 133 (06) : S9 - S9
  • [12] Improved and cleared facial and hand dermatitis with lebrikizumab in patients with moderate-to-severe atopic dermatitis
    Murase, Jenny E.
    Chovatiya, Raj
    Strowd, Lindsay
    Thyssen, Jacob P.
    Bangert, Christine
    Atwater, Amber Reck
    Gallo, Gaia
    Bardolet, Laia
    Yang, Fan
    Zhong, Jinglin
    Staumont-Salle, Delphine
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [13] Intriguing findings on lebrikizumab for treating moderate-to-severe atopic dermatitis
    Arents, Bernd W. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (06) : 694 - 694
  • [14] Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis
    Cork, M. J.
    Eichenfield, L. F.
    Blauvelt, A.
    Rosmarin, D.
    Hussain, I.
    Davis, J. D.
    Li, M.
    Zhang, Q.
    Gadkari, A.
    Eckert, L.
    Kamal, M. A.
    Bansal, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S104 - S104
  • [15] Lebrikizumab reduces systemic inflammation in serum of patients with moderate-to-severe atopic dermatitis
    Guttman-Yassky, Emma
    Okragly, Angela
    Sun, Zhe
    Mena, Laura Rebeca
    Hahn, Nathan
    Nickoloff, Brian J.
    Siu, Kimberly
    Gallo, Gaia
    Wolf, Eric
    Eyerich, Kilian
    Aparici, Monica
    Benschop, Robert J.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II4 - II5
  • [16] Lebrikizumab reduces systemic inflammation in serum of patients with moderate-to-severe atopic dermatitis
    Guttman-Yassky, E.
    Okragly, A.
    Sun, Z.
    Mena, L. R.
    Hahn, N.
    Nickoloff, B. J.
    Siu, K.
    Gallo, G.
    Wolf, E.
    Eyerich, K.
    Aparici, M.
    Benschop, R. J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S364 - S364
  • [17] Lebrikizumab reduces systemic inflammation in serum of patients with moderate-to-severe atopic dermatitis
    Guttman-Yassky, E.
    Okragly, A.
    Sun, Z.
    Mena, L.
    Hahn, N.
    Nickoloff, B.
    Siu, K.
    Gallo, G.
    Wolf, E.
    Eyerich, K.
    Aparici, M.
    Benschop, R.
    EXPERIMENTAL DERMATOLOGY, 2024, 33 (03)
  • [18] The efficacy and safety of lebrikizumab monotherapy for the management of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis
    Bashrahil, Bader
    Alzahrani, Ziyad
    Samarkandy, Sahal
    Aman, Abdullah
    Jfri, Abdulhadi
    FRONTIERS IN MEDICINE, 2023, 9
  • [19] Maintenance of efficacy and safety with lebrikizumab up to one year of treatment in patients with moderate-to-severe atopic dermatitis with or without topical corticosteroids
    Guttman-Yassky, E.
    Weidinger, S.
    Silverberg, J.
    Gooderham, M.
    Thyssen, J.
    Irvine, A.
    Elmaraghy, H.
    Natalie, C.
    Hu, C.
    Pierce, E.
    Gil, E. G.
    Simpson, E.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S348 - S348
  • [20] Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergies
    Schmid-Grendelmeier, Peter
    Gooderham, Melinda J.
    Hartmann, Karin
    Konstantinou, George N.
    Fellmann, Marc
    Koulias, Christopher
    Clibborn, Claire
    Biswas, Pinaki
    Brunner, Patrick M.
    ALLERGY, 2024, 79 (01) : 174 - 183
12345